These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37354015)

  • 41. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
    Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
    Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amentoflavone derivatives significantly act towards the main protease (3CL
    Dey D; Hossain R; Biswas P; Paul P; Islam MA; Ema TI; Gain BK; Hasan MM; Bibi S; Islam MT; Rahman MA; Kim B
    Mol Divers; 2023 Apr; 27(2):857-871. PubMed ID: 35639226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
    Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
    Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
    Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
    J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M
    Elgohary AM; Elfiky AA; Pereira F; Abd El-Aziz TM; Sobeh M; Arafa RK; El-Demerdash A
    Comput Biol Med; 2022 Aug; 147():105738. PubMed ID: 35777088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.
    Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF
    J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
    Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches.
    Raj V; Park JG; Cho KH; Choi P; Kim T; Ham J; Lee J
    Int J Biol Macromol; 2021 Jan; 168():474-485. PubMed ID: 33290767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consensus Pharmacophore Strategy For Identifying Novel SARS-Cov-2 M
    Ruiz-Moreno AJ; Cedillo-González R; Cordova-Bahena L; An Z; Medina-Franco JL; Velasco-Velázquez MA
    J Chem Inf Model; 2024 Mar; 64(6):1984-1995. PubMed ID: 38472094
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
    Chakraborti S; Bheemireddy S; Srinivasan N
    Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2.
    Joshi RP; Schultz KJ; Wilson JW; Kruel A; Varikoti RA; Kombala CJ; Kneller DW; Galanie S; Phillips G; Zhang Q; Coates L; Parvathareddy J; Surendranathan S; Kong Y; Clyde A; Ramanathan A; Jonsson CB; Brandvold KR; Zhou M; Head MS; Kovalevsky A; Kumar N
    J Chem Inf Model; 2023 Mar; 63(5):1438-1453. PubMed ID: 36808989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors.
    Previti S; Ettari R; Calcaterra E; Di Maro S; Hammerschmidt SJ; Müller C; Ziebuhr J; Schirmeister T; Cosconati S; Zappalà M
    Eur J Med Chem; 2023 Feb; 247():115021. PubMed ID: 36549112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.
    Gimeno A; Mestres-Truyol J; Ojeda-Montes MJ; Macip G; Saldivar-Espinoza B; Cereto-Massagué A; Pujadas G; Garcia-Vallvé S
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allosteric inhibitors of the main protease of SARS-CoV-2.
    Samrat SK; Xu J; Xie X; Gianti E; Chen H; Zou J; Pattis JG; Elokely K; Lee H; Li Z; Klein ML; Shi PY; Zhou J; Li H
    Antiviral Res; 2022 Sep; 205():105381. PubMed ID: 35835291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
    Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
    SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
    Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
    Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.